Journal List > Korean Diabetes J > v.33(2) > 1002275

Kim, Rhee, Choi, Won, Park, Lee, Oh, Kim, Sung, Kim, Kang, Park, Kim, Lee, and Park: The Relationship between Serum Retinol-Binding Protein 4 Levels and Coronary Artery Disease in Korean Adults

Abstract

Background

A recently discovered adipokine, retinol-binding protein-4 (RBP-4), is reportedly associated with insulin resistance and metabolic syndrome. This study was performed to analyze the relationship between serum RBP-4 levels and coronary artery disease (CAD) in Korean adults.

Methods

In 235 subjects (mean age 58 years) in whom coronary artery angiograms were performed due to complaints of chest pain, serum RBP-4 levels were measured by enzyme-linked immunosorbent assay. Coronary artery angiograms were performed in all subjects and the severity of CAD was assessed by the number of stenotic vessels. The presence of metabolic syndrome was defined by AHA/NHLBI criteria with body mass index substituted for waist circumference.

Results

Coronary angiogram showed that 101 subjects (43%) had normal coronary vessel, 82 subjects (34.9%) had 1-vessel disease, 31 subjects (13.2%) had 2-vessel disease and 21 subjects (8.9%) had 3-vessel disease. Subjects with coronary artery stenosis showed a higher mean age (60.5 ± 10.0 years), fasting glucose (123.3 mg ± 45.0 mg/dL) and lower mean value for high-density lipoprotein cholesterol (HDL-C) level (49.0 ± 13.2 mg/dL), although serum RBP-4 levels were not significantly different between those with and without CAD. Mean age and fasting glucose level increased significantly as the number of stenotic vessels increased, although serum RBP4 level showed no significant differences among the different groups. Among the metabolic parameters, only serum triglyceride levels showed a significant correlation with serum RBP-4 levels.

Conclusion

There was no difference in mean serum RBP-4 levels between subjects with or without coronary artery disease in Korean adults. Further studies are warranted to draw a clear conclusion on the effect of RBP-4 on atherosclerosis.

Figures and Tables

Table 1
Baseline characteristics of the participants
kdj-33-105-i001

Data was given as mean ± SD and number of cases (%). BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RBP-4, retinol-binding protein-4.

Table 2
Comparisons of the variables according to the presence of coronary artery stenosis
kdj-33-105-i002

Data was given as mean ± SD. *Analyses were performed with Student's t-test. BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RBP-4, retinol-binding protein-4.

Table 3
Comparisons of the variables according to the number of stenotic vessels
kdj-33-105-i003

Data was given as mean ± SD. *Analyses were performed with one-way ANOVA test. BMI, body mass index; BP, blood pressure; FBS, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RBP-4, retinol-binding protein-4; TC, total cholesterol; TG, triglyceride.

Table 4
Bivariate correlation coefficient between the metabolic parameters and serum RBP4 level
kdj-33-105-i004

*P < 0.05 in bivariate correlation analyses, P < 0.01 in bivariate correlation analyses. BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RBP-4, retinol-binding protein-4; SBP, systolic blood pressure; T-chol, total cholesterol; TG, triglyceride.

Table 5
Comparisons of the variables according to the metabolic disease status defined by AHA/NHLBI
kdj-33-105-i005

Data was given as mean ± SD. AHA/NHLBI, American Heart association/National Heart, Lung, and Blood Institute; BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RBP-4, retinol-binding protein-4.

References

1. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008. 93:suppl 1. S64–S73.
crossref
2. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008. 29:351–366.
3. Deedwania P. Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients. J Clin Hypertens (Greenwich). 2007. 9:883–888.
crossref
4. Gallagher EJ, LeRoith D, Karnieli E. The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am. 2008. 37:559–579.
crossref
5. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005. 436:356–362.
crossref
6. Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, Lin X. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007. 92:4827–4834.
crossref
7. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinol-binding protein-4concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006. 29:2457–2461.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.
9. Mallat Z, Simon T, Benessiano J, Clément K, Taleb S, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab. 2009. 94:255–260.
crossref
10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005. 112:2735–2752.
11. WHO Western Pacific Region, IASO and IOTF. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. 2000. Sydney, Australia: Health Communications Australia Pty Limit.
12. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004. 27:1047–1055.
crossref
13. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005. 365:1398–1405.
crossref
14. Bulcao C, Ferreira SR, Giuffrida FM, Ribeiro-Filho FF. The new adipose tissue and adipocytokines. Curr Diabetes Rev. 2006. 2:19–28.
crossref
15. van Dam RM, Hu FB. Lipocalins and Insulin Resistance: Etiological Role of Retinol-Binding Protein 4 and Lipocalin-2. Clin Chem. 2007. 53:5–7.
crossref
16. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007. 92:1971–1974.
crossref
17. Shepherd PR, Kahn BB. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999. 341:248–257.
18. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006. 354:2552–2563.
crossref
19. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, Sharma AM, Jordan J. Retinol-binding protein 4 in human obesity. Diabetes. 2006. 55:2805–2810.
crossref
20. Erikstrup C, Mortensen OH, Pedersen BK. Retinol-binding protein 4 and insulin resistance. N Engl J Med. 2006. 355:1393–1394.
crossref
TOOLS
Similar articles